title: Short term effects of exercise training on exercise capacity and quality of life in patients with pulmonary arterial hypertension: protocol for a randomised controlled trial.
abstract: BACKGROUND
  Advances in the understanding and management of pulmonary arterial hypertension have enabled earlier diagnosis and improved prognosis. However, despite best available therapy, symptoms of exertional dyspnoea and fatigue are commonly reported and result in a reduced capacity to perform daily activities and impaired quality of life. Exercise training has demonstrated efficacy in individuals with other respiratory and cardiovascular diseases. Historically, however, exercise training has not been utilised as a form of therapy in pulmonary arterial hypertension due to the perceived risk of sudden cardiac death and the theoretical possibility that exercise would lead to worsening pulmonary vascular haemodynamics and deterioration in right heart function. Now, with the advances in pharmaceutical management, determining the safety and benefits of exercise training in this population has become more relevant. Only three studies of supervised exercise training in pulmonary arterial hypertension have been published. These studies demonstrated improvements in exercise capacity and quality of life, in the absence of adverse events or clinical deterioration. However, these studies have not utilised an outpatient-based, whole body exercise training program, the most common format for exercise programs within Australia. It is uncertain whether this form of training is beneficial and capable of producing sustained benefits in exercise capacity and quality of life in this population.
  
  
  METHODS
  This randomised controlled trial will determine whether a 12 week, outpatient-based, supervised, whole body exercise training program, followed by a home-based exercise program, is safe and improves exercise capacity and quality of life in individuals with pulmonary arterial hypertension. This study aims to recruit 34 subjects who will be randomly allocated to the exercise group (supervised exercise training 3 times a week for 12 weeks, followed by 3 sessions per week of home exercise for 12 weeks) or the control group (usual medical care). Subjects will be assessed at baseline, 12 weeks and 24 weeks.
  
  
  CONCLUSIONS
  This study will determine whether outpatient-based, whole body exercise training is beneficial and safe in individuals with pulmonary arterial hypertension. Additionally, this study will contribute to clinical practice guidelines for this patient population.
  
  
  BACKGROUND
  Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12609000502235.
authors: School of Physiotherapy and Curtin Health Innovation Research Institute, Curtin University, Perth, Australia. louise.ganderton@health.wa.gov.au
authors: Louise
authors: L
authors: Ganderton
authors: Sue
authors: S
authors: Jenkins
authors: Kevin
authors: K
authors: Gain
authors: Robin
authors: R
authors: Fowler
authors: Peta
authors: P
authors: Winship
authors: Dianne
authors: D
authors: Lunt
authors: Eli
authors: E
authors: Gabbay
references: Ann Clin Res. 1971 Dec;3(6):404-32
references: 4945367
references: Eur Respir J. 2009 Sep;34(3):669-75
references: 19720810
references: Med Sci Sports Exerc. 1982;14(5):377-81
references: 7154893
references: Intern Med J. 2007 Jan;37(1):38-48
references: 17199843
references: Circulation. 2008 Jun 10;117(23):3010-9
references: 18506008
references: Med J Aust. 2002 Nov 18;177(10):565-7
references: 12429008
references: N Engl J Med. 1997 Jan 9;336(2):111-7
references: 8988890
references: Am J Respir Crit Care Med. 2003 Jan 15;167(2):211-77
references: 12524257
references: Am J Respir Crit Care Med. 2006 Jun 15;173(12):1390-413
references: 16760357
references: Res Q Exerc Sport. 2000 Jun;71(2 Suppl):S114-20
references: 10925833
references: Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003793
references: 17054186
references: Qual Life Res. 2006 Feb;15(1):103-15
references: 16411035
references: Qual Life Res. 2007 May;16(4):661-73
references: 17268926
references: Cardiopulm Phys Ther J. 2009 Dec;20(4):12-8
references: 20467524
references: Circulation. 2008 Sep 9;118(11):1195-201
references: 18779455
references: Eur Respir J. 2005 Jan;25(1):125-30
references: 15640333
references: Circulation. 2004 Sep 7;110(10):1308-12
references: 15337703
references: Circulation. 2006 Oct 3;114(14):1482-9
references: 16982941
references: Lancet. 2001 Apr 14;357(9263):1191-4
references: 11323066
references: Am J Respir Crit Care Med. 2005 Jul 1;172(1):19-38
references: 15778487
references: Heart Fail Rev. 2008 Feb;13(1):61-8
references: 17939037
references: Thorax. 2010 Feb;65(2):113-7
references: 19720606
references: Circulation. 2003 Mar 4;107(8):1210-25
references: 12615804
references: Control Clin Trials. 2000 Jun;21(3):167-89
references: 10822117
references: Control Clin Trials. 1999 Aug;20(4):319-27
references: 10440559
references: Cochrane Database Syst Rev. 2004;(3):CD003331
references: 15266480
references: Chest. 2007 May;131(5 Suppl):4S-42S
references: 17494825
references: J Am Coll Cardiol. 2009 Apr 28;53(17):1573-619
references: 19389575
references: Respirology. 2011 Nov;16(8):1235-40
references: 21810146
references: Respir Med. 2007 Nov;101(11):2366-9
references: 17689235
references: Circulation. 2001 Jul 24;104(4):429-35
references: 11468205
references: Clin Sci (Lond). 2008 Jan;114(2):165-71
references: 17764445
references: J Heart Lung Transplant. 2010 Feb;29(2):159-73
references: 19969471
references: J Physiol Pharmacol. 2007 Nov;58 Suppl 5(Pt 2):591-602
references: 18204173
references: J Cardiopulm Rehabil Prev. 2008 Jan-Feb;28(1):12-6
references: 18277824
references: J Cardiol. 2005 Nov;46(5):183-93
references: 16320975
references: J Appl Physiol (1985). 2000 May;88(5):1565-70
references: 10797113
references: Eur Respir J. 2005 Jan;25(1):6-8
references: 15640315
references: Circulation. 1999 Mar 9;99(9):1173-82
references: 10069785